Validation experiment designed to validate causal mechanisms targeting NAMPT in AOM/DSS-treated mice. Primary outcome: Tumor development and inflammatory markers
Evaluation of FK866's therapeutic potential in preventing inflammation-associated tumorigenesis using the azoxymethane (AOM)/DSS model of colitis-associated cancer in mice. This experiment assessed whether NAMPT inhibition could suppress both inflammatory processes and tumor development in the context of chronic intestinal inflammation. The study demonstrated that FK866 treatment effectively suppressed inflammation-associated tumorigenesis, indicating that NAD metabolism plays a crucial role not only in acute inflammation but also in the progression from chronic inflammation to cancer.
Sequential AOM and DSS treatment to induce colitis-associated cancer followed by FK866 intervention with assessment of tumor formation and inflammatory parameters
Reduced tumor formation and suppressed inflammatory tumorigenesis
Decreased tumor incidence and size, reduced inflammatory markers
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.